STAMFORD, Conn. -- World-renowned scientist and University of Pittsburgh School of Medicine genetics and biochemistry professor Joseph Glorioso III has been named chairman of the Scientific Advisory Council at the Alliance for Cancer Gene Therapy in Stamford.
Glorioso is known for his work on the molecular and genetic aspects of the herpes simplex virus and how to better engineer this organism as a vector for transporting therapeutic genes. He will take the helm from Dr. Savio L.C. Woo, founding chairman of ACGT’s Scientific Advisory Council; Woo also was named the council's chairman emeritus.
“Savio has been a remarkable and dynamic leader who has steered the council from the beginning to focus on young investigators and groundbreaking clinical translation,” Glorioso said.
“This work has resulted in (the Alliance) pioneering breakthroughs in gene and cell therapy treatments for cancer. We now look forward, to expanding our vision to include later-stage research, which will be very exciting.”
Glorioso received his bachelor’s degree and doctorate from Louisiana State University before joining the University of Michigan Medical School in the late 1970s.
He attained the rank of professor and assistant dean for research and graduate studies there, and then joined the University of Pittsburgh School of Medicine in 1989. At Pittsburgh, Glorioso served as professor and chairman of the Department of Molecular Genetics and Biochemistry, as well as the McEllroy Professorship in Biochemistry, until 2009.
Glorioso continues his groundbreaking work in the development of herpes viral vectors for the treatment of cancer, chronic pain and diseases of the central nervous system. He has served on ACGT’s Scientific Advisory Council since 2005.
“Joe has been a valuable member of our Scientific Advisory Council and has made tremendous strides in his own work to improve the quality of life for patients fighting cancer and other diseases; that same vision will advance ACGT’s own pursuit of effective cell and gene therapy treatments,” said Barbara Netter, ACGT's president and co-founder.
ACGT’s Scientific Advisory Council, composed of pre-eminent physicians and researchers in cell and gene therapy, serves without compensation and establishes the scientific criteria for the review of all grants. Council members also are tasked with developing strict accountability guidelines requiring periodic progress reports. The council is made up of 15 members, including Glorioso.
Click here to sign up for Daily Voice's free daily emails and news alerts.